ADC Therapeutics is a biotechnology company focused on the development of antibody drug conjugates, or ADCs, which combine an antibody, a linker, and a therapeutic payload to target cancer cells. Its research has centered strongly on hematologic cancers, with ZYNLONTA serving as its primary commercial product. The company continues to investigate ways to expand the role of this therapy while developing additional ADC approaches for oncology.
Antibody drug conjugates are designed to connect targeted biological recognition with the delivery of a potent therapeutic payload. This approach is intended to direct treatment toward cells carrying a particular antigen while providing a mechanism for destroying those cells. ADC Therapeutics has developed expertise across antibody selection, linker technology, payload design, and drug development.
ZYNLONTA, also known as loncastuximab tesirine, is a CD19 directed ADC. It has received accelerated approval in the United States for adults with relapsed or refractory diffuse large B cell lymphoma after two or more lines of systemic therapy. The company is also pursuing additional applications through clinical research.
Key areas of research include:
These efforts demonstrate how modern oncology research increasingly examines therapies not only as individual treatments but also as components of broader treatment strategies.
ADC Therapeutics has also explored next generation ADC technology beyond its established lymphoma program. One important research direction is ADCT 241, a PSMA targeting ADC being developed for prostate cancer. According to the company's 2025 annual report, IND enabling activities for this candidate were completed, and the company continues to explore potential partnering opportunities. The candidate uses an exatecan based payload and a hydrophilic linker.
Modern oncology research involving ADCs continues to focus on improving the balance between treatment activity and tolerability. Important research considerations include:
ADC Therapeutics' current strategy reflects a more focused research approach, with resources directed toward expanding ZYNLONTA and advancing its PSMA targeting ADC while discontinuing earlier preclinical solid tumor programs.
Overall, ADC Therapeutics illustrates the continuing evolution of targeted oncology research. Its work with ZYNLONTA and emerging ADC candidates demonstrates how researchers are investigating targeted delivery systems, combination treatments, and new biological targets. As clinical studies progress, future findings will help determine which approaches can provide meaningful benefits for people with different types and stages of cancer. This information is provided for educational purposes and does not represent medical advice, treatment recommendations, sales, or healthcare services.